Application 125320

Type
BLA
Sponsor
AMGEN

Related Records

Application Products

ProductDrugIngredientFormStrengthReference drugReference standard
001PROLIADENOSUMABINJECTABLE; SUBCUTANEOUS60MG/MLNoNo
002XGEVADENOSUMABINJECTABLE; SUBCUTANEOUS70MG/MLNoNo

NDC Listings For This Application

NDCNameNonproprietary nameLabelerMarketing categoryStatus
55513-710ProliadenosumabAmgen IncBLACurrent
55513-710ProliadenosumabAmgen IncBLACurrent
55513-710ProliadenosumabAmgen IncBLACurrent
55513-710ProliadenosumabAmgen IncBLACurrent
55513-710ProliadenosumabAmgen IncBLACurrent
55513-710ProliadenosumabAmgen IncBLACurrent
55513-710ProliadenosumabAmgen IncBLACurrent
55513-710ProliadenosumabAmgen IncBLACurrent
55513-730XGEVAdenosumabAmgen IncBLACurrent
55513-730XGEVAdenosumabAmgen IncBLACurrent
55513-730XGEVAdenosumabAmgen IncBLACurrent
55513-730XGEVAdenosumabAmgen IncBLACurrent
55513-730XGEVAdenosumabAmgen IncBLACurrent
55513-730XGEVAdenosumabAmgen IncBLACurrent
55513-730XGEVAdenosumabAmgen IncBLACurrent

Documents

DocumentSubmission typeDate
82428SUPPL 2025-06-02
82421SUPPL 2025-06-02
82409SUPPL 2025-06-02
82408SUPPL 2025-06-02
82320SUPPL 2025-05-27
82158SUPPL 2025-05-05
82134SUPPL 2025-05-05
78107SUPPL 2024-04-10
77733SUPPL 2024-03-06
77715SUPPL 2024-03-05
77714SUPPL 2024-03-05
77265SUPPL 2024-01-22
77248SUPPL 2024-01-22
73100SUPPL2023-01-05
73099SUPPL2023-01-05
73081SUPPL2023-01-04
71109SUPPL2022-05-20
71107SUPPL2022-05-20
71106SUPPL2022-05-20
67483SUPPL2021-05-13
67482SUPPL2021-05-13
67478SUPPL2021-05-13
63568SUPPL2020-06-15
63477SUPPL2020-06-10
62673SUPPL2020-04-24
62669SUPPL2020-04-24
62668SUPPL2020-04-24
61863SUPPL2020-02-11
61862SUPPL2020-02-11
60215SUPPL2019-10-03
60189SUPPL2019-10-02
60188SUPPL2019-10-02
59496SUPPL2019-07-30
59480SUPPL2019-07-29
58953SUPPL2019-06-04
58870SUPPL2019-05-29
58690SUPPL2019-05-14
58689SUPPL2019-05-14
58644SUPPL2019-05-13
58643SUPPL2019-05-13
58511SUPPL2019-05-02
58500SUPPL2019-05-01
57220SUPPL2019-01-15
57219SUPPL2019-01-15
56508SUPPL2018-11-20
54564SUPPL2018-06-14
54496SUPPL2018-06-11
43320SUPPL2018-06-05
54285SUPPL2018-05-22
54278SUPPL2018-05-21
51909SUPPL2018-01-26
51905SUPPL2018-01-26
51006SUPPL2018-01-09
50980SUPPL2018-01-04
48569SUPPL2017-05-30
48571SUPPL2017-05-26
47075SUPPL2017-01-31
45538SUPPL2016-10-17
45537SUPPL2016-10-17
45039SUPPL2016-08-05
45031SUPPL2016-08-05
45026SUPPL2016-08-05
45025SUPPL2016-08-05
45024SUPPL2016-08-05
45023SUPPL2016-08-05
45014SUPPL2016-08-05
45013SUPPL2016-08-05
45011SUPPL2016-08-05
45010SUPPL2016-08-05
45009SUPPL2016-08-05
45008SUPPL2016-08-05
45007SUPPL2016-08-05
31930SUPPL2016-03-04
18871SUPPL2016-03-04
31929SUPPL2015-06-10
18870SUPPL2015-06-10
9707SUPPL2015-05-26
9709SUPPL2015-04-13
39929SUPPL2015-04-10
39928SUPPL2015-03-02
9708SUPPL2015-03-02
39927SUPPL2014-12-10
9706SUPPL2014-12-09
9704SUPPL2014-06-18
39926SUPPL2014-06-17
9705SUPPL2014-06-05
18869SUPPL2014-06-04
39925SUPPL2013-08-27
39924SUPPL2013-08-27
9703SUPPL2013-08-27
9702SUPPL2013-08-27
31928SUPPL2013-07-08
39923SUPPL2013-07-05
39922SUPPL2013-06-13
31927SUPPL2013-06-13
31925SUPPL2013-02-20
18867SUPPL2013-02-20
18865SUPPL2012-09-25
31923SUPPL2012-09-24
31926SUPPL2012-09-18